Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, FMI International Equity. This analysis is provided for institutional research purposes only and is not investment advice.
"FMI International Equity posted -7.41% in Q4 but achieved 2.72% YTD returns through concentrated large-cap international investing. The fund added ICON at cyclical trough valuations while exiting Arch Capital after strong performance."
FMI International Equity delivered a -7.41% net return in Q4 2024 but achieved positive 2.72% YTD performance, slightly underperforming the MSCI EAFE benchmark. The portfolio maintains 33 holdings concentrated in large-cap international companies, with top positions including Booking Holdings, Ferguson Enterprises, and Sodexo. The fund's investment philosophy centers on purchasing durable business franchises at discounts to intrinsic value, emphasizing strong recurring revenue and attractive returns on invested capital. During the quarter, FMI initiated a 2.0% position in ICON, a global contract research organization, capitalizing on what appears to be a cyclical trough in the CRO industry following pharmaceutical industry pipeline rationalization. The firm sold its remaining position in Arch Capital Group after strong performance, seeking better risk-reward opportunities. The portfolio maintains a long-term investment horizon with typical holding periods of three to five years and 20-40% annual turnover, focusing on quality businesses with strong management teams.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The portfolio demonstrates moderate-high conviction with 33 concentrated holdings, specific position sizing (2.0% ICON, 1.5% ACGL), and detailed thesis explanations for individual names. The manager provides clear rationale for both purchases and sales with specific business analysis.
Growth Outlook
The manager identifies a cyclical trough in the CRO industry and describes current valuations as providing attractive entry points, suggesting selective optimism despite acknowledging industry headwinds.
Risk Appetite
The portfolio shows selective risk-taking with a new 2.0% position in ICON while harvesting gains from ACGL, indicating measured positioning rather than aggressive deployment.
Capital Deployment
The manager initiated one new 2.0% position while selling a 1.5% position, representing minimal net capital deployment. This appears to be rotation rather than significant new money deployment.
Forward Guidance
The manager indicates selective deployment at attractive valuations but provides limited forward guidance on broader portfolio actions or market timing.
Language Signal
Language includes positive terms like 'attractive entry point,' 'quality,' and 'competitive differentiation' balanced against 'tightened capital availability' and 'slowed growth,' resulting in mildly positive directional language.
Perceived Risk
The manager acknowledges specific industry risks including tightened capital availability and pharmaceutical pipeline rationalization, but frames these as cyclical rather than systemic concerns.
Opportunity Density
The manager identifies selective opportunities in cyclical troughs but also indicates the need to seek 'better risk/reward opportunities,' suggesting a mixed opportunity environment requiring selectivity.
Time Horizon
The fund explicitly states a long-term investment approach with typical holding periods of three to five years and emphasizes being long-term investors, indicating a multi-year investment horizon.
